# MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients

> **NCT06044493** · PHASE4 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 158 (actual)

## Conditions studied

- Kidney Transplant

## Interventions

- **DRUG:** Myreptic-N Tablet
- **DRUG:** Mycophenolate mofetil Tablet/Capsule

## Key facts

- **NCT ID:** NCT06044493
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-14
- **Primary completion:** 2025-10-29
- **Final completion:** 2025-10-29
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06044493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06044493, "MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06044493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*